PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Breast Cancer

In brief

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving letrozole together with lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This randomized phase II trial is studying how well giving letrozole together with lapatinib works in treating postmenopausal women with stage I, stage II, or stage III breast cancer that can be removed by surgery.

Key facts

Study ID

NCT00499681

Run by

Vanderbilt-Ingram Cancer Center

People needed

6

Starts

2007-07-01

Expected to finish

2010-12-01

Last updated by the study team

2012-08-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Clinical stage I, II, or III operable invasive mammary carcinoma, confirmed by histological analysis
• Measurable residual tumor at the primary site
• Measurable disease is defined as any mass that can be reproducibly measured by physical examination, mammogram, and/or ultrasound and can be accurately measured in at least one dimension (longest diameter to be recorded) as 10 mm (1 cm)
• Available core biopsies from the time of diagnosis
• May include sections of paraffin-embedded material
• Scheduled to undergo surgical treatment with either segmental resection or total mastectomy
• Prior history of contralateral breast cancer allowed if patient has no evidence of recurrence of their initial primary breast cancer within the last 5 years
• HER2-positive by Herceptest (3+) or FISH
• ER-positive and/or PR-positive by IHC

You may not qualify if…

• Locally recurrent breast cancer
• Evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases)
• PATIENT CHARACTERISTICS:
• Inclusion Criteria:
• Female
• Postmenopausal, as defined by any of the following:
• At least 55 years of age
• Under 55 years of age and amenorrheic for at least 12 months OR follicle-stimulating hormone (FSH) values ≥ 40 IU/L and estradiol levels ≤ 20 IU/L
• Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months
• ECOG performance status 0-1
• ANC ≥ 1,000/mm³
• Platelet count ≥ 100,000/mm³
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• AST and ALT ≤ 1.5 times ULN
• Able to swallow and retain oral medication
• Cardiac ejection fraction normal by echocardiogram (or MUGA scan if an echocardiogram cannot be performed or is inconclusive)
• Exclusion Criteria:
• Premenopausal breast cancer, pregnant, or lactating
• Serious medical illness, that in the judgment of the treating physician, places the patient at high risk of operative mortality
• Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel
• Ulcerative colitis
• History of other malignancy
• Patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinomas are eligible
• Active or uncontrolled infection

Where it is running

• Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center at Franklin — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.